Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-31871085

RESUMO

Many antibiotics carry caution stickers that warn against alcohol consumption. Data regarding concurrent use are sparse. An awareness of data that address this common clinical scenario is important so health care professionals can make informed clinical decisions and address questions in an evidence-based manner. The purpose of this systematic review was to determine the evidence behind alcohol warnings issued for many common antimicrobials. The search was conducted from inception of each database to 2018 using PubMed, Medline via Ovid, and Embase. It included studies that involved interactions, effects on efficacy, and toxicity/adverse drug reactions (ADR) due to concomitant alcohol consumption and antimicrobials. All interactions were considered in terms of three components: (i) alteration in pharmacokinetics/pharmacodynamics (PK/PD) of antimicrobials and/or alcohol, (ii) change in antimicrobial efficacy, and (iii) development of toxicity/ADR. Available data support that oral penicillins, cefdinir, cefpodoxime, fluoroquinolones, azithromycin, tetracycline, nitrofurantoin, secnidazole, tinidazole, and fluconazole can be safely used with concomitant alcohol consumption. Data are equivocal for trimethoprim-sulfamethoxazole. Erythromycin may have reduced efficacy with alcohol consumption, and doxycycline may have reduced efficacy in chronic alcoholism. Alcohol low in tyramine may be consumed with oxazolidinones. The disulfiram-like reaction, though classically associated with metronidazole, occurs with uncertain frequency and with varied severity. Cephalosporins with a methylthiotetrazole (MTT) side chain or a methylthiodioxotriazine (MTDT) ring, ketoconazole, and griseofulvin have an increased risk of a disulfiram-like reaction. Alcohol and antimicrobial interactions are often lacking evidence. This review questions common beliefs due to poor, often conflicting data and identifies important knowledge gaps.


Assuntos
Álcoois/efeitos adversos , Álcoois/farmacocinética , Antibacterianos/efeitos adversos , Antibacterianos/farmacocinética , Anti-Infecciosos/efeitos adversos , Anti-Infecciosos/farmacocinética , Azitromicina/efeitos adversos , Azitromicina/farmacocinética , Cefalosporinas/efeitos adversos , Cefalosporinas/farmacocinética , Doxiciclina/efeitos adversos , Doxiciclina/farmacocinética , Interações Medicamentosas , Eritromicina/efeitos adversos , Eritromicina/farmacocinética , Fluoroquinolonas/efeitos adversos , Fluoroquinolonas/farmacocinética , Metronidazol/efeitos adversos , Metronidazol/análogos & derivados , Metronidazol/farmacocinética , Penicilinas/efeitos adversos , Penicilinas/farmacocinética , Tetraciclina/efeitos adversos , Tetraciclina/farmacocinética
2.
Innov Clin Neurosci ; 16(7-08): 22-24, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31832260

RESUMO

Clozapine, a second-generation antipsychotic (SGA), is known for its superior efficacy in the treatment of refractory schizophrenia. Clozapine's hallmark side effects are well-known, including, but not limited to, drug-induced seizures associated with daily goal doses greater than 600mg and rapid dose escalation, which can also contribute to significant risk of orthostatic hypotension, bradycardia, and syncope. However, less well-known is the potential withdrawal that can occur from its rapid discontinuation. Here, we describe a case of seizure-like activity that occurred 72 hours after an abrupt high-dose clozapine discontinuation in a patient with schizoaffective disorder, bipolar type. Seizures, although known to be a high-serum-concentration-dependent side effect of clozapine, could not be excluded as a possible withdrawal syndrome in this patient.

3.
Int Clin Psychopharmacol ; 34(1): 45-50, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30422835

RESUMO

According to the National Alliance on Mental Illness, one in five adults experience a mental health condition yearly. Community-acquired pneumonia (CAP) is often treated with QTc prolonging antibiotics. The primary outcome assessed is if psychiatric diagnosis contributed to treatment failure in CAP. Outpatients with International Statistical Classification of Diseases and Related Health Problems 9 and 10 codes for CAP from January 2008 to January 2018 were analyzed retrospectively by descriptive statistics. Bivariate analysis was used to compare baseline characteristics, treatment regimens, and outcomes between those with a psychiatric diagnosis and those without. A χ-test was used for analysis of categorical variables and either the independent Student's t-test or one-way analysis of variance was used was used for analysis of continuous variables. Criteria were met by 518 patients, of which, 49% had a psychiatric diagnosis. Patients with psychiatric comorbidity were not more likely to experience treatment failure, subsequent admission, or mortality. There was no statistically significant difference between patients with a psychiatric diagnosis and those without in early or late CAP treatment failure (P=0.34 and 0.12), 30-day subsequent admission rates (P=0.41), 30-day mortality (P=0.34), or 90-day mortality (P=0.38). Psychiatric diagnosis increased the likelihood of a concomitant QTc prolonging psychiatric medication (51.78 vs. 3.40% P<0.0001), however, the prescribing rate of a QTc prolonging antibiotic was not statistically significantly different (85.3 vs. 83.4% P=0.54). Outpatients with mental illness can be treated for CAP without fear of increased risk of treatment failure compared with those without such diagnosis. This study emphasizes the necessity to consider the full patient history and diagnosis when treating patients with outpatient infections.


Assuntos
Antibacterianos/uso terapêutico , Antipsicóticos/uso terapêutico , Transtornos Mentais/tratamento farmacológico , Transtornos Mentais/epidemiologia , Pneumonia/tratamento farmacológico , Pneumonia/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/efeitos adversos , Antibacterianos/farmacologia , Infecções Comunitárias Adquiridas , Interações Medicamentosas , Eletrocardiografia , Feminino , Humanos , Masculino , Transtornos Mentais/fisiopatologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença , Oxibato de Sódio , Resultado do Tratamento
4.
Clin Ther ; 41(3): 466-476, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30739721

RESUMO

PURPOSE: Community-acquired pneumonia (CAP) is one of the leading causes of death in the United States. The primary objective of this study was to determine the prevalence of appropriate diagnosis and treatment of outpatients treated for CAP. Knowledge of problems with CAP treatment can be helpful in developing stewardship initiatives to improve care of outpatients with CAP. METHODS: Included in this study were patients 18 years and older who received antibiotic therapy for the treatment of CAP in the outpatient setting. Outpatients were identified by International Classification of Diseases, Ninth Revision (ICD-9) and International Classification of Diseases, Tenth Revision (ICD-10) codes for CAP in the Veterans Affairs Western New York Healthcare System between January 2008 and January 2018. Appropriate treatment was evaluated using CAP guidelines. Factors associated with an inappropriate regimen were determined via multivariable analyses. FINDINGS: This study included 518 outpatients, of whom 66% were appropriately diagnosed with CAP. Of the 341 appropriately diagnosed patients, only 31% received an antibiotic regimen consistent with guidelines. Regarding inappropriate regimens, 76.7% contained an incorrect drug based on patient comorbidities, and 39.4% consisted of an inappropriate duration, which was most often attributable to prolonged length of therapy >7 days. The odds of being prescribed an inappropriate regimen if a patient was considered to be at risk for drug-resistant Streptococcus pneumoniae (DRSP) was 4.2 (95% CI, 2.4-7.4). The population at risk for DRSP was more likely to present to the health care system again within 30 days compared with low-risk patients (19.4% vs 8.7%, P = 0.005). IMPLICATIONS: Improvement in prescribing is needed for CAP. An outpatient stewardship program that targets patients with risk factors for DRSP would improve adherence to guidelines.


Assuntos
Antibacterianos/uso terapêutico , Gestão de Antimicrobianos , Infecções Comunitárias Adquiridas/tratamento farmacológico , Pacientes Ambulatoriais , Pneumonia/tratamento farmacológico , Idoso , Feminino , Humanos , Prescrição Inadequada , Masculino , Pessoa de Meia-Idade , New York , Padrões de Prática Médica , Prevalência , Fatores de Risco , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa